918-P: Fully Closed Loop (FCL) System Improves Glycemic Control through Personalized Adaptation of Individual Insulin Needs in Adults, Young Adults, and Adolescents with Type 1 Diabetes (T1D)

by sugaradmin



Introduction and Objective: The Automated Insulin Delivery as Adaptive NETwork (AIDANET) FCL adjusts its aggressiveness based on glycemic metrics computed from the last 14-days of CGM records, to adapt to the different insulin requirements that individuals may have. The system was tested in a broad cohort of people with T1D. We report changes in glycemic outcomes during home use.Methods: Participants enrolled in a randomized crossover trial across three age cohorts (14-17, 18-25 or 26-60 years) and two HbA1c groups (<8% or 8-12%). Depending on their 1:1 randomization, 2-week usual care data was collected either before or after completing a 5-day hotel stay for AID system training followed by the 7-day at-home period. AIDANET tunes control aggressiveness via a single parameter, defined as estimated Total Daily Insulin (eTDI), adjusted by a change factor (eTDIα) to minimize time below range 70 mg/dL (TBR) and time above range 180 mg/dL (TAR). eTDIα<1 implies a decreased eTDI.Results: Thirty-four participants completed the study. eTDI was reduced (eTDIα<1, Figure) when TBR increased and increased when reduced time in range (with increased TAR) was observed. TBR was reduced from start to end of the home period (-1.62%; p=0.048) while maintaining low TAR via the eTDI modulation.Conclusion: AIDANET adaptation system achieved reduced hypoglycemia by tailoring eTDI to each individual.

Disclosure

M. Moscoso-Vasquez: Other Relationship; Dexcom, Inc. Research Support; Tandem Diabetes Care, Inc, National Institute of Diabetes and Digestive and Kidney Diseases. D. Flanagan: None. M. Clancy-Oliveri: None. E. Escobar: None. D. Fulkerson: None. G.P. Forlenza: Advisory Panel; Medtronic. Research Support; Medtronic, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Tandem Diabetes Care, Inc. Advisory Panel; Tandem Diabetes Care, Inc. Research Support; Abbott. Advisory Panel; Sequel Med Tech. L. Ekhlaspour: Other Relationship; Medtronic. Advisory Panel; Abbott, Medtronic. Consultant; Jaeb Center for Health Research. Research Support; MannKind Corporation. Speaker’s Bureau; Insulet Corporation. Advisory Panel; Sequel Med Tech. Other Relationship; Tandem Diabetes Care, Inc. Research Support; Abbott. Other Relationship; Sanofi. S.A. Brown: Research Support; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc, Tolerion, Roche Diabetes Care. Other Relationship; MannKind Corporation. M.D. Breton: Speaker’s Bureau; Sinocare Inc, Tandem Diabetes Care, Inc. Consultant; Roche Diabetes Care, Boydsense.

Funding

Breakthrough Type 1 Diabetes (2-SRA-2023-1275-M-B)



Source link